| Background：Primary hepatocellular carcinoma (HCC hepatocellu1ar carcinoma)isthe most common digestive system, and is also higher morbidity andmortality are one of the tumor. about600000people died of liver cancereach year in the world, of which China accounts for about50%andRanked third in cancer mortality, liver cancer has some features:malignant degree is high, the growth speed and the recurrence rate is high,the transfer range is wide, especially advanced liver cancer, medianoverall survival is less than3months. The treatment of liver cancerresection is still the preferred method, but advanced liver cancer patientsoften lose timing of surgery. For unresectable HCC, hepatic arteryembolism chemotherapy embolization (TACE) is the most effectivetreatment method. But TACE usually cannot make lesions completenecrosis, and the recurrence rate is high, a large number of studies haveshown that the recurrent cause closely related with tumor angiogenesis,so looking for new treatment methods to improve the treatment of livercancer survival is at present need urgent need to solve the problem. Thedata shows, sorafenib has inhibiting tumor cell proliferation andangiogenesis of the dual role of advanced liver cancer，patients canimprove overall survival, it is the comprehensive treatment of livercancer research hot spot. molecular targeted drugs-sorafenibcombined by hepatic arterial chemotherapy embolization (TACE) treatment of advanced hepatocellular carcinoma (HCC) clinical curativeeffect, safety and feasibility is discussed. it provides reference forclinical.Objective：To explore clinical curative effect, safety and feasibility on themolecular targeted drugs-sorafenib combined by hepatic arterialchemotherapy embolization (TACE) treatment of advancedhepatocellular carcinoma (HCC).Methods：By the prospective research methods, according to the randommatching principle,62cases patients with advanced liver cancer weredivided into treatment group and control group from January2011toJanuary2012. The observation group have sorafenib combined byhepatic arterial chemotherapy embolization (TACE) treatment, controlgroup only with hepatic arterial chemotherapy embolization (TACE)treatment, before and after treatment, the clinical efficacy of liverfunction and serum VEGF and AFP level, side effects and prognosis oftwo groups patients were compared.Results1.The observation group and the control group before treatment andafter treatment of4weeks, liver function index ALT, TBIL, ALB andindex were compared, the difference was not statistically significant (P>0.05).2.Before treatment and after treatment of4weeks, the observationgroup and the control group of serum VEGF level were compared, theobservation group after treatment of VEGF value (184.2±21.0ng/ml, control group was213.6±27.5ng/ml, the difference was statisticallysignificant (P <0.05). By comparison between group, the difference wasstatistically significant (P <0.05).3.Before treatment and after treatment of4weeks, the observationgroup and the control group of serum VEGF level were compared, theobservation group after treatment of VEGF value (184.2±21.0ng/ml,control group (213.6±27.5ng/ml, the difference was statisticallysignificant (P <0.05). By comparison between group, the difference wasstatistically significant (P <0.05).4.The observation group and the control group in accordance with theside effects of the brotherhood of syndrome, diarrhea, bone marrowsuppression, gastrointestinal reaction, fatigue, skin rashes, high bloodpressure and liver function abnormalities were compared, the brotherssyndrome, diarrhea, skin rash, hypertension incidence higher than thosein the control group, the difference was statistically significant (P <0.05).5.According to the results of follow-up, the observation group andcontrol group of between Kaplan-Meier survival curve, the observationgroup, the median survival time was177.5days, and the control groupsurvival time was111.875days. Two groups of survival is (Log-Ranktest) chi-square value is12.241, the two groups of survival differencewas statistically significant (P <0.05)ConclusionMolecular targeted drugs-sorafenib combined by hepatic arterialchemotherapy embolization (TACE) treatment of advancedhepatocellular carcinoma (HCC) is effective and reliable, safe, and it canprolong survival time in patients, it is the first choice of treatment for the treatment of advanced liver cancer. |
PDF Full Text Request